ArticleResearch square2025
An Observational Study of SGLT2 Inhibitors and Their Use in Autosomal Dominant Tubulointerstitial Kidney Disease.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: There are no specific treatments available for autosomal dominant tubulointerstitial kidney disease (ADTKD). As SGLT2 inhibitors have proven effective in other forms of CKD, we performed an observational study to determine their safety and effect on kidney function in ADTKD. Methods: We obtained clinical and laboratory data before and after starting an SGLT2 inhibitor on 27 individuals with ADTKD. We created a propensity-matched cohort from a Wake Forest prospective ADTKD observational study. Results: Of the 27 individuals, 12 stopped medication prior to one year due to concerns about the (anticipated) acute rise in serum creatinine. There were no adverse effects. The slope of eGFR after SGLT 2 inhibitor initiation was - 2.61 ± 2.58 ml/min/1.73m Conclusions: SGLT2 inhibitors were well tolerated in ADTKD patients. There was neither a rise in hemoglobin levels nor a fall in plasma or urinary KIM-1 levels, suggesting that these agents may not be beneficial in ADTKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.